Search

Search Results

• GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload

  Vincenzo De Sanctis, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis , Salvatore Di Maio, Christos Kattamis

  e2023006

  2023-01-01

  https://doi.org/10.4084/MJHID.2023.006

  3832

  PDF: 1070

  HTML: 414

• BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.

  Roberto Castelli

  e2016030

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.030

  4272

  PDF: 955

  HTML: 1648

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5191

  PDF: 1889

  HTML: 1333

• INFECTIOUS AETIOLOGY OF MARGINAL ZONE LYMPHOMA AND ROLE OF ANTI-INFECTIVE THERAPY

  Salvatore Perrone, Gianna Maria D'Elia, Alessandro Pulsoni

  e2016006

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.006

  4393

  PDF: 1301

  HTML: 2143

• LONGITUDINAL STUDY ON LIVER FUNCTIONS IN PATIENTS WITH THALASSEMIA MAJOR BEFORE AND AFTER DEFERASIROX (DFX) THERAPY

  Ashraf Tawfik Soliman, Mohamed Yassin, Fawzia AlYafei, Lolwa Al-Naimi, Noora Almarri, Aml Sabt, Vincenzo De Sanctis

  e2014025

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.025

  2151

  PDF: 2104

  HTML: 2404

• EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA

  Linjuan Xu

  e2025058

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.058

  1360

  PDF: 722

  Suppl. Files: 307

  Html: 123

• Late-onset hepatic veno-occlusive disease after allografting: report of two cases with atypical clinical features successfully treated with defibrotide.

  Alessia Castellino, Stefano Guidi, Chiara Dellacasa, Antonella Gozzini, Irene Donnini, Chiara Nozzoli, Sara Manetta, Semra Aydin, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Enrico Maffini, Benedetto Bruno, Ezio David, Alessandro Busca

  e2018001

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.001

  4039

  PDF: 979

  HTML: 978

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1262

  HTML: 113

  PDF: 824

• QUALITY OF LIFE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS UNDERGOING DOSE-REDUCED TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION

  Alhossain A. Khalafallah, Kristina McDonnell, Hizb U. Dawar, Iain Robertson, David Woods

  e2011057

  2011-11-28

  https://doi.org/10.4084/mjhid.2011.057

  1362

  PDF: 655

  HTML: 1368

  cover letter: 193

• 5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

  Mariangela Greco, Marianna Criscuolo, Luana Fianchi, Livio Pagano, Maria Teresa Voso

  e2011011

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.011

  1547

  PDF: 742

  HTML: 1098

• THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA

  adel abd elhaleim hagag

  e2013065

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.065

  2521

  PDF: 805

  HTML: 14930

  Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 277

• DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA

  Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos

  e2019016

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.016

  1830

  PDF: 1091

  HTML: 239

• Addition of daratumumab to first-line therapy of newly diagnosed multiple myeloma in patients eligible for autologous stem cell transplantation: a single-center real-life experience

  Edoardo Olivari

  e2025040

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.040

  972

  PDF: 737

  HTML: 141

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2106

  PDF: 1947

  HTML: 146

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1632

  PDF: 628

  HTML: 2416

• AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS

  Grzegorz Helbig, Malgorzata Krawczyk-Kulis, Malgorzata Kopera, Krystyna Jagoda, Patrycja Rzepka, Aleksandra Majewska-Tessar, Marta Hejla, Slawomira Kyrcz-Krzemien

  e2014047

  2014-06-29

  https://doi.org/10.4084/mjhid.2014.047

  1499

  PDF: 885

  HTML: 1937

  Figure: 158

  Tables: 175

  ALL revision 1: 179

  response to reviewer: 166

• THE USE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE COMPLICATIONS OF CHRONIC LYMPHOCYTIC LEUKEMIA

  Luca Laurenti

  e2013027

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.027

  2083

  PDF: 1009

  HTML: 2694

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2810

  PDF: 1398

  HTML: 3040

  Cover Letter: 187

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT IN FOLLICULAR LYMPHOMAS

  Mónica Cabrero, Alba Redondo, Alejandro Martin, Dolores Caballero

  e2012074

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.074

  2119

  PDF: 711

  HTML: 1058

• Challenging management of severe differentiation syndrome in pediatric acute promyelocytic leukemia treated with ATRA/ATO

  Alessandro Molinaro, Daniela Zanta, Maria Luisa Moleti, Fiorina Giona, Valentino Conter, Carmelo Rizzari, Andrea Biondi, Anna Maria Testi

  e2022027

  2022-02-27

  https://doi.org/10.4084/MJHID.2022.027

  1668

  HTML: 223

  PDF: 575

• THALIDOMIDE FOR PATIENTS WITH THALASSEMIA INTERMEDIA: A RETROSPECTIVE MULTICENTER CLINICAL STUDY

  Kun Yang, Yi Wu, Yali Zhou, Tianhong Zhou, Li Wang, Zhili Geng, Xiaolin Yin

  e2020021

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.021

  2096

  PDF: 1185

  HTML: 303

• THE DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA: EXPERIENCE OF THE PETHEMA GROUP AND REVIEW OF THE LITERATURE.

  Pau Montesinos, Miguel A Sanz

  e2011059

  2011-12-04

  https://doi.org/10.4084/mjhid.2011.059

  2976

  PDF: 1481

  HTML: 2408

• PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries

  Dr, Moleti, Anna Maria Testi

  e2024078

  2024-10-31

  https://doi.org/10.4084/MJHID.2024.078

  1210

  PDF: 823

  HTML: 262

• INVASIVE CANDIDIASIS IN NON-HEMATOLOGICAL PATIENTS.

  Malgorzata Mikulska, Matteo Bassetti, Sandra Ratto, Claudio Viscoli

  e2011007

  2011-01-25

  https://doi.org/10.4084/mjhid.2011.007

  2233

  PDF: 921

  HTML: 11108

• Impressive continuous complete response after mogamulizumab in a heavily pre-treated Sézary syndrome patient

  Pier Luigi Zinzani, Ginevra Lolli, Beatrice Casadei, Lisa Argnani, Laura Nanni, Michele Cavo

  e2020040

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.040

  988

  PDF: 654

  HTML: 192

• OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONINIG REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE

  Francesca Patriarca, Andrea Bacigalupo, Alessandra Sperotto, Miriam Isola, Maria Teresa Van Lint, Anna Paola Iori, Paolo Di Bartolomeo, Maurizio Musso, Pietro Pioltelli, Giuseppe Visani, Pasquale Iacopino, Renato Fanin, Alberto Bosi

  e2010010

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.010

  1467

  PDF: 751

  HTML: 752

• CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment

  Michele Malagola, Raffaella Greco, Stella Santarone, Anna Paola Iori, Luisa Quatrocchi, Walter Barberi, Bruzzese Antonella, Salvatore Leotta, Alessandra Carotti, Antonio Pierini, Simon Bernardi, Enrico Morello, Nicola Polverelli, Alessandro Turra, Federica Cattina, Lisa Gandolfi, Benedetta Rambaldi, Francesca Lorentino, Francesca Serio, Annalisa Natale, Giuseppe Milone, Andrea Velardi, Robin Foà, Fabio Ciceri, Domenico Russo, Jacopo Peccatori

  e2019048

  2019-08-29

  https://doi.org/10.4084/mjhid.2019.048

  1880

  PDF: 1137

  HTML: 256

• Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

  Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà, Maria Teresa Petrucci

  e2012035

  2012-05-07

  https://doi.org/10.4084/mjhid.2012.035

  1471

  PDF: 713

  HTML: 614

• TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

  Charicleia Kelaidi, Lionel Ades, Pierre Fenaux

  e2011038

  2011-09-08

  https://doi.org/10.4084/mjhid.2011.038

  2407

  PDF: 911

  HTML: 2318

• CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Rafael de la Camara

  e2016031

  2016-06-20

  https://doi.org/10.4084/mjhid.2016.031

  4729

  PDF: 1725

  HTML: 2690

  Untitled: 197

• A A RETROSPECTIVE LONG-TERM STUDY ON AGE AT MENARCHE AND MENSTRUAL CHARACTERISTICS IN 85 YOUNG WOMEN WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) BORN BETWEEN 1965 AND 1995 Long-Term Study on Age at Menarche and Menstrual Characteristics in patients with TDT

  Vincenzo De Sanctis, Salvatore Di Maio

  e2021040

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.040

  1447

  PDF: 464

  HTML: 166

• HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PAEDIATRIC PATIENTS WITH X-LINKED LYMPHOPROLIFERATIVE SYNDROME

  Yuan Sun

  e2024036

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.036

  1271

  PDF: 1118

  HTML: 150

• ROLE OF COMORBIDITIES IN OPTIMIZING DECISION-MAKING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

  Mohamed L. Sorror, Rainer F. Storb

  e2010015

  2010-06-08

  https://doi.org/10.4084/mjhid.2010.015

  958

  PDF: 611

  HTML: 2198

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3684

  PDF: 1035

  HTML: 1869

• IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

  Tomasz Sacha

  e2014007

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.007

  4590

  PDF: 2755

  HTML: 2253

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1491

  PDF: 772

  HTML: 130

• IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES

  Paolo Cianciulli

  e2009034

  1220

  PDF: 602

  HTML: 2300

• LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING

  Jassada Buaboonnam, Chayamon Takpradit, Vip Viprakasit, Nattee Narkbunnam, Nassawee Vathana, Kamon Phuakpet, Kleebsabai Sanpakit, Bunchoo Pongtanakul

  e2021065

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.065

  1084

  PDF: 388

  HTML: 145

• Guest Editor: Raffaella Origa IRON TOXICITY AND HEMOPOIETIC CELL TRANSPLANTATION: TIME TO CHANGE THE PARADIGM. IRON TOXICITY AND HEMOPOIETIC CELL TRANSPLANTATION

  Federica Pilo

  e2019030

  2019-04-25

  https://doi.org/10.4084/mjhid.2019.030

  1870

  PDF: 1197

  HTML: 225

• HEMATOPOIETIC STEM CELL TRNSPLANTATION IN THALASSEMIA AND RELATED DISORDERS

  Emanuele Angelucci, Federica Pilo, Clara Targhetta, Martina Pettinau, Cristina Depau, Claudia Cogoni, Sara Usai, Mario Pani, Laura Dessì, Donatella Baronciani

  e2009015

  1365

  PDF: 480

  HTML: 3944

• A rare immune-related mesenteric and retroperitoneal serositis in a multirefractory Hodgkin lymphoma patient successfully treated with chylolymphostatic surgery

  Matteo D'Addona, Luca Pezzullo, Corradino Campisi, Corrado Cesare Campisi, Valentina Giudice, Vincenzo Ciccone, Roberto Guariglia, Bianca Serio, Carmine Selleri

  e2023063

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.063

  641

  PDF: 370

  HTML: 120

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1558

  PDF: 1047

  HTML: 102

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2449

  PDF: 822

  HTML: 8793

  Efremov 1: 208

  Efremov 2: 170

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  1801

  PDF: 1543

  HTML: 115

• MANAGING INVASIVE FUNGAL INFECTIONS DURING ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION: A 2025 UPDATE

  Martina Quattrone, Alessia Di Pilla, Sara Brunetti, Antonio Giordano, Luana Fianchi, Livio Pagano, Marianna Criscuolo

  e2025064

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.064

  1892

  PDF: 781

  HTML: 156

• FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

  Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni

  e2024066

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.066

  1026

  PDF: 596

  Html: 136

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1247

  HTML: 286

  PDF: 907

  Suppl. Files: 434

• ASSESSMENT OF OBESITY AND HEPATIC LATE ADVERSE EFFECTS IN THE EGYPTIAN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER STUDY

  Farida El-Rashedy, Mahmoud Ahmed El-Hawy, Sally El Hefnawy, Mona Mohammed

  e2017026

  2017-04-15

  https://doi.org/10.4084/mjhid.2017.026

  2449

  PDF: 859

  HTML: 1277

  Untitled: 208

• TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment

  Alessandro Buonomo, Eleonora Nucera, Marianna Criscuolo

  e2022040

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.040

  1998

  PDF: 1476

  HTML: 260

• THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

  Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

  e2010009

  2010-05-03

  https://doi.org/10.4084/mjhid.2010.009

  1042

  PDF: 688

  HTML: 601